Repare Therapeutics Inc. (NASDAQ:RPTX) Sees Significant Decline in Short Interest

Repare Therapeutics Inc. (NASDAQ:RPTX) saw a significant drop in short interest in November. As of November 15th, there was short interest totalling 609,900 shares, a drop of 18.6% from the October 31st total of 749,700 shares. Based on an average trading volume of 116,000 shares, the short-interest ratio is currently 5.3 days. Currently, 2.1% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Repare Therapeutics in a research note on Friday, November 8th.

Repare Therapeutics Stock Down 1.2 %

Shares of NASDAQ:RPTX opened at $3.28 on Monday. Repare Therapeutics has a 52 week low of $2.71 and a 52 week high of $8.49. The stock has a market capitalization of $139.44 million, a P/E ratio of -1.64 and a beta of 0.72. The firm has a fifty day simple moving average of $3.38 and a two-hundred day simple moving average of $3.37.

Hedge Funds Weigh In On Repare Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Barclays PLC boosted its stake in shares of Repare Therapeutics by 1,471.7% during the 3rd quarter. Barclays PLC now owns 8,330 shares of the company’s stock worth $29,000 after purchasing an additional 7,800 shares during the period. Vontobel Holding Ltd. boosted its stake in shares of Repare Therapeutics by 20.0% during the 3rd quarter. Vontobel Holding Ltd. now owns 24,000 shares of the company’s stock worth $83,000 after purchasing an additional 4,000 shares during the period. XTX Topco Ltd purchased a new position in shares of Repare Therapeutics during the 2nd quarter worth about $110,000. Exchange Traded Concepts LLC boosted its stake in shares of Repare Therapeutics by 21.2% during the 3rd quarter. Exchange Traded Concepts LLC now owns 50,441 shares of the company’s stock worth $174,000 after purchasing an additional 8,809 shares during the period. Finally, Stifel Financial Corp boosted its stake in shares of Repare Therapeutics by 36.4% during the 3rd quarter. Stifel Financial Corp now owns 51,700 shares of the company’s stock worth $178,000 after purchasing an additional 13,800 shares during the period. 85.09% of the stock is owned by hedge funds and other institutional investors.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.